COURT-RULING ·Filed May 28, 2026

ABT

ABBOTT LABORATORIES
NEUTRAL
Impact 1/10
Horizonimmediate Processed4mo ago CourtView Ruling on CourtListener
Court ruling (appellate)
Actionable Insight • Neutral

This ruling has no material impact on Abbott's stock. The case was a pro se employment suit dismissed at the pleading stage, and the affirmance merely confirms that outcome. No further action or monitoring is warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
ABT ▲ +35.24% at T+60d
NEUTRAL call ✓ call won +35.24% · α vs SPY +33.77% · entry $86.24 → $116.63
Entry anchored
May 27, 03:59 PM ET
via exchange tick
T+1d
-0.86%
call -0.86% · α -1.10%
$85.50
settled 4mo ago
T+5d
+0.87%
call +0.87% · α +0.92%
$86.99
settled 4mo ago
T+20d
+8.12%
call +8.12% · α +10.81%
$93.24
settled 3mo ago
T+60d
+35.24%
call +35.24% · α +33.77%
$116.63
settled 6w ago

Price Chart

Loading chart...

Executive Summary

The Ninth Circuit affirmed the district court's dismissal of a pro se plaintiff's employment claims against Abbott Laboratories for failure to state a claim. The ruling is a complete win for Abbott, removing a trivial litigation risk with no financial exposure.

Court Ruling Details

Ruling Date
May 28, 2026
Court
United States Court of Appeals for the Ninth Circuit
Court Level
Appellate
Judge
S.R. Thomas, Miller, H.A. Thomas
Case Type
employment
Ruling Type
final judgment
Outcome
WIN — ruling favors this company
Will It Be Appealed?
N/A (final)
Precedent Risk
LOW

Key Facts

  • Ninth Circuit affirmed dismissal of employment claims against Abbott Laboratories
  • Plaintiff Mazen Arakji failed to allege facts sufficient to state a plausible claim
  • Ruling is a final judgment in Abbott's favor with no damages awarded or sought
  • Case involved routine employment claims with no material financial exposure

Financial Impact

No damages awarded or pleaded; case dismissed with no financial impact on Abbott

Market Snapshot

Price
$85.82
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (35 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 court opinion from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-1w7g8o9x-ABT
22 reports for ABT
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +17.16%Jul 1, 2026
Filters
Rows
Reports for ABT — sortable, filterable
TypeNow
Oct 2, 2026
today
ANALYST-UPGRADE
BULLISH ★ 4/10
$98.00 awaiting T+5awaiting T+5—$95.39 (−2.67%)
Sep 14, 2026
18d ago
Court Ruling
NEUTRAL ★ 1/10
$103.09 $102.98▼ −0.11%▼ −1.77%$95.39 (−7.47%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 2/10
$109.72 $112.68▲ +2.70%▲ +3.10%$95.39 (−13.06%)
Aug 11, 2026
7w ago
Court Ruling
NEUTRAL ★ 1/10
$109.72 $112.68▲ +2.70%▲ +3.10%$95.39 (−13.06%)
Jul 31, 2026
9w ago
Institutional Cluster
MIXED ★ 4/10
$105.70 $107.81▲ +2.00%▼ −1.51%$95.39 (−9.76%)
Jul 31, 2026
9w ago
Court Ruling
NEUTRAL ★ 2/10
$105.70 $107.81▲ +2.00%▼ −1.51%$95.39 (−9.76%)
Jul 24, 2026
10w ago
Court Ruling
BULLISH ★ 5/10
$103.06 $105.61▲ +2.47%▲ +2.10%$95.39 (−7.44%)
Jul 16, 2026
11w ago
8-K
BULLISH ★ 6/10
$98.83 $100.75▲ +1.94%▲ +3.61%$95.39 (−3.48%)
Jul 14, 2026
11w ago
Court Ruling
NEUTRAL ★ 3/10
$88.96 $101.66▲ +14.28%▲ +15.57%$95.39 (+7.23%)
Jul 7, 2026
12w ago
Court Ruling
NEUTRAL ★ 1/10
$95.84 $88.96▼ −7.18%▼ −7.73%$95.39 (−0.47%)
Showing 10 of 22

US Market Status

Market Open — Closes in 6h 23m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access